Physician profile
Ryan James Wright
NPI 1154559433
$7,705.25
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,212 · 2020: $2,483 · 2021: $2,305 · 2022: $648 · 2023: $56.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $56.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $56.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,194.17 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $824.99 | 2019-2022 | |
| Abbvie INC. | $664.80 | 2021-2023 | Vraylar |
| Allergan, INC. | $648.71 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $596.89 | 2020-2023 | |
| Mdd US Operations, LLC | $536.43 | 2019-2020 | |
| Uswm, LLC | $397.45 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $391.43 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $355.43 | 2019-2022 | |
| Alkermes, INC. | $341.33 | 2019-2022 | |
| Lundbeck LLC | $294.80 | 2019-2021 | |
| Bausch Health US, LLC | $268.69 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $203.72 | 2019-2021 | |
| Adlon Therapeutics L.P. | $157.09 | 2020-2021 | |
| Indivior INC. | $135.62 | 2019-2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Noven Therapeutics, LLC | $125.66 | 2020-2021 | |
| Eisai INC. | $110.16 | 2020-2021 | |
| Gilead Sciences, INC. | $103.36 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $100.21 | 2019-2021 | |
| Brainsway USA INC | $48.74 | 2019-2022 | |
| Novo Nordisk INC | $35.54 | 2021 | |
| Owp Pharmaceuticals, INC. | $30.93 | 2022 | |
| Merck Sharp & Dohme LLC | $29.44 | 2021 | |
| Avanir Pharmaceuticals, INC. | $23.69 | 2019 | |
| Noven Pharmaceuticals, INC. | $22.07 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $20.43 | 2020 | |
| Livanova USA, INC. | $18.04 | 2021 | |
| Arbor Pharmaceuticals, INC. | $13.52 | 2020 | |
| Alfasigma USA, INC. | $11.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.